✦ LIBER ✦

Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease

✍ Scribed by Winblad, Bengt; Machado, João Carlos

Book ID: 120239946
Publisher: Informa plc
Year: 2008
Tongue: English
Weight: 806 KB
Volume: 5
Category: Article
ISSN: 1742-5247
DOI: 10.1517/17425240802542690

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Drug Profile: Transdermal Rivastigmine P

Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease

✍ Murat Emre; Roberto Bernabei; Rafael Blesa; Roger Bullock; Luis Cunha; Hugo Dani 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

Pharmacokinetics of a novel transdermal

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review

✍ A. Kurz; M. Farlow; G. Lefèvre 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB

Transdermal rivastigmine in the treatmen

Transdermal rivastigmine in the treatment of Alzheimer’s disease: current and future directions

✍ Amanatkar, Hamid Reza; Grossberg, George Thomas 📂 Article 📅 2014 🏛 Expert Reviews 🌐 English ⚖ 221 KB

Rivastigmine transdermal patches in the

Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study

✍ Prasher, V. P.; Sachdeva, N.; Adams, C.; Haque, M. S. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Rivastigmine transdermal system for the

Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer’s disease

✍ G. T. Grossberg; C. Sadowsky; J. T. Olin 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

Rivastigmine transdermal patch and capsu

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy

✍ Martin R. Farlow; George T. Grossberg; Xiangyi Meng; Jason Olin; Monique Somogyi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 373 KB

## Abstract ## Objectives The cholinesterase inhibitor rivastigmine is approved for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). This exploratory, hypothesis‐forming analysis assessed response to rivastigmine according to severity of dementia at baseline. ## Methods Th